Investments
1225Portfolio Exits
99Partners & Customers
1Expert Collections containing Horizon 2020
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find Horizon 2020 in 1 Expert Collection, including Beauty & Personal Care.
Beauty & Personal Care
58 items
Startups in the beauty & personal care space, including cosmetics brands, shaving startups, on-demand beauty services, salon management platforms, and more.
Horizon 2020 Web Traffic
Horizon 2020 Rank
Latest Horizon 2020 News
Jun 24, 2022
This report is intended to provide the reader with an in-depth understanding and access to Biosimilars trends and structure of deals entered into by leading companies worldwide. The report provides a detailed understanding and analysis of how and why companies enter Biosimilars partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors Biosimilars technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not. This report contains links to online copies of actual Biosimilars deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. Global Biosimilars Partnering Terms and Agreements 2010 to 2022 includes: Trends in Biosimilars dealmaking in the biopharma industry since 2010 Access to headline, upfront, milestone and royalty data Access to over 190 Biosimilars deal records and contract documents where available The leading Biosimilar deals by value since 2010 Most active Biosimilars dealmakers since 2010 The leading Biosimilars partnering resources Key Topics Covered:
Horizon 2020 Investments
1,225 Investments
Horizon 2020 has made 1,225 investments. Their latest investment was in Octavic as part of their Grant on June 6, 2022.
Horizon 2020 Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
6/13/2022 | Grant | Octavic | $0.8M | Yes | EFPF, Innovation Norway, and Sensative | 1 |
3/3/2022 | Grant | Waste2Func | $7.4M | Yes | 1 | |
8/26/2021 | Grant - III | Sleepiz | $3.26M | No | 1 | |
7/27/2021 | Seed VC | |||||
7/22/2021 | Grant |
Date | 6/13/2022 | 3/3/2022 | 8/26/2021 | 7/27/2021 | 7/22/2021 |
---|---|---|---|---|---|
Round | Grant | Grant | Grant - III | Seed VC | Grant |
Company | Octavic | Waste2Func | Sleepiz | ||
Amount | $0.8M | $7.4M | $3.26M | ||
New? | Yes | Yes | No | ||
Co-Investors | EFPF, Innovation Norway, and Sensative | ||||
Sources | 1 | 1 | 1 |
Horizon 2020 Portfolio Exits
99 Portfolio Exits
Horizon 2020 has 99 portfolio exits. Their latest portfolio exit was eLEAF on May 25, 2022.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
5/25/2022 | Corporate Majority | 1 | |||
5/5/2022 | Acq - Fin | 2 | |||
5/5/2022 | Acquired | 1 | |||
Date | 5/25/2022 | 5/5/2022 | 5/5/2022 | ||
---|---|---|---|---|---|
Exit | Corporate Majority | Acq - Fin | Acquired | ||
Companies | |||||
Valuation | |||||
Acquirer | |||||
Sources | 1 | 2 | 1 |
Horizon 2020 Partners & Customers
1 Partners and customers
Horizon 2020 has 1 strategic partners and customers. Horizon 2020 recently partnered with Euformatics on October 10, 2018.
Date | Type | Business Partner | Country | News Snippet | Sources |
---|---|---|---|---|---|
10/25/2018 | Vendor | Finland | Euformatics selected for GEMMA project to provide genomics analysis and quality control for Autism Spectrum Disorders . | 2 |
Date | 10/25/2018 |
---|---|
Type | Vendor |
Business Partner | |
Country | Finland |
News Snippet | Euformatics selected for GEMMA project to provide genomics analysis and quality control for Autism Spectrum Disorders . |
Sources | 2 |
Horizon 2020 Team
1 Team Member
Horizon 2020 has 1 team member, including current General Partner, Robert-Jan Smits.
Name | Work History | Title | Status |
---|---|---|---|
Robert-Jan Smits | General Partner | Current |
Name | Robert-Jan Smits |
---|---|
Work History | |
Title | General Partner |
Status | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.